Laura J. Havrilesky

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu

Amanda N. Fader, Dana M. Roque, Eric R. Siegel et al. · Journal of Clinical Oncology · 2018 · 509 citations · Full text

Retrospective Analysis of Selective Lymphadenectomy in Apparent Early-Stage Endometrial Cancer

Janiel M. Cragun, Laura J. Havrilesky, Brian Calingaert et al. · Journal of Clinical Oncology · 2005 · 444 citations

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

Robert J. Morgan, Deborah K. Armstrong, Ronald D. Alvarez et al. · Journal of the National Comprehensive Cancer Network · 2016 · 318 citations · Full text

Cancer Management, Gynecology, Pathology +18

Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

Amanda N. Fader, Dana M. Roque, Eric R. Siegel et al. · Clinical Cancer Research · 2020 · 292 citations · Full text

FDG-PET for management of cervical and ovarian cancer

Laura J. Havrilesky, Shalini Kulasingam, David B. Matchar et al. · Gynecologic Oncology · 2005 · 253 citations

Positron Emission Tomography, Cervical Cancer Management, Cervical Cancer +7